Dorzagliatin and 1st Phase Insulin and Beta-cell Glucose Sensitivity in IGT and NGT

Exclusion Criteria

• •1. Subjects who do not agree to participate in this study.
• •2. Country of birth is unknown.
• •3. Body weight less than 45kg.
• •4. Acute phase of cerebrovascular and cardiovascular diseases (within 6 months of recruitment).
• •5. Subjects with severe renal dysfunction as defined by eGFR \<30 ml/min/1.73m2 or patients receiving renal dialysis (such as haemodialysis or continuous ambulatory peritoneal dialysis).
• •6. Severe hepatic dysfunction as defined by AST and/or ALT \> 3 times upper limit of normal.
• •7. Severe cardiovascular disease, history of stroke, heart failure (NYHA III or IV) or history of myocardial infarction within last 12 months.
• •8. History of drug abuse or excessive alcohol intake based on investigator judgment.
• •9. History of diabetes mellitus.
• •10. Dehydration, diarrhoea or vomiting at the time of recruitment.
• •11. Subjects with severe infection, in perioperative period or with serious injury at the time of recruitment.
• •12. Subjects with anaemia (Haemoglobin \<11.0mg/dL or haematocrit \<0.35 ) at screening, known iron deficiency, haemoglobinopathies or anaemia due to chronic disease.
• •13. Pregnant or lactating or intending to become pregnant within 30 days after last dose of study drug.
• •14. Participation in a clinical trial with investigational product within 30 days before enrolment.
• •15. Donation or loss of blood (excluding the volume of blood that will be drawn during screening procedures) as follows: ≥300 mL of blood within 30 days prior to study drug administration.
• •16. Subjects judged unsuitable for the study based on investigator judgment.
• •17. Use of strong or moderate CYP3A4 inhibitors or inducers and cannot be discontinued.
• •18. Unwilling or unable to follow protocol requirements